Bevacizumab and ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 1, 2012, Pages 8-13

  Sato, Shinya ^a   Itamochi, Hiroaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

angiogenesis; bevacizumab; molecular targeted therapy; ovarian cancer; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MONOTHERAPY; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTENSION; INTESTINAL PERFORATION; OVARIAN NEOPLASMS; PACLITAXEL; PROTEINURIA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855809821     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32834daeed     Document Type: Review

References (45)

1. Global Cancer Facts & Figures 2007. Available from http://www.cancer.org/Research/CancerFactsFigures/GlobalCancerFactsFigures/ global-cancerfacts- figures-2007.
2. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl. 1):S161-S192.
3. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248-1259. (Pubitemid 34177431)
4. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27:1419-1425.
5. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinumsensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009; 19 (Suppl. 2):S63-S67.
6. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3:502-516. (Pubitemid 37328838)
7. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8:579-591.
8. Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem 2010; 1:209-220.
9. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61. (Pubitemid 19115892)
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364. (Pubitemid 26272076)
11. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007; 25:2894-2901. (Pubitemid 47123153)
12. Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-165.
13. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974. (Pubitemid 43093963)
14. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011; 12: 551-564.
15. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049. (Pubitemid 351656458)
16. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78:1379-1384. (Pubitemid 28495254)
17. Ohta Y, Tomita Y, Oda M, et al. Tumor angiogenesis and recurrence in stage I nonsmall cell lung cancer. Ann Thorac Surg 1999; 68:1034-1038. (Pubitemid 29526880)
18. Shimogai R, Kigawa J, Itamochi H, et al. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 2008; 18:499-505. (Pubitemid 351668322)
19. Klasa-Mazurkiewicz D, Jarzab M, Milczek T, et al. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 2011; 62:31-40.
20. Siddiqui GK, Elmasry K, Wong Te Fong AC, et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol 2010; 31:156-159.
21. Chen H, Ye D, Xie X, et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004; 94:630-635. (Pubitemid 39194453)
22. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004; 24:1973-1979. (Pubitemid 38954620)
23. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006; 103:512-517. (Pubitemid 44740099)
24. Siddiqui GK, Maclean AB, Elmasry K, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis 2011; 14:155-161.
25. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87:506-516.
26. Sher I, Adham SA, Petrik J, et al. AutocrineVEGF-A/KDRloop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009; 124:553-561.
27. Spannuth WA, Nick AM, Jennings NB, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009; 124:1045-1053.
28. Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18:185-197.
29. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7:53-64.
30. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844. (Pubitemid 23132159)
31. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62. (Pubitemid 40093472)
32. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171. (Pubitemid 350237599)
33. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-5186. (Pubitemid 350232248)
34. Chura JC, Van Iseghem K, Downs LS Jr, et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007; 107:326-330. (Pubitemid 47575735)
35. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76-82.
36. McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a Phase 2 Study. Cancer 2010; 117:3731-3740.
37. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010; 28:154-159.
38. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a gynecologic oncology study. J Clin Oncol 2010; 28(Suppl.):abstr LBA1.
39. Kristensen G, Perren T, Qian W, et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011; 29(Suppl.): abstr LBA5006.
40. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, doubleblinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29(Suppl.):abstr LBA5007.
41. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007; 105:3-6. (Pubitemid 46441477)
42. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305:487-494.
43. Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29:1247-1251.
44. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21:2460-2465. (Pubitemid 46606325)
45. Lesnock JL, Farris C, Krivak TC, et al. Consolidation paclitaxel is more costeffective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol 2011; 122:473-478.